

WE MAKE
MORE THAN
MEDICINES

We make it better.



accord

Contents

Global key facts	3
Accord at a glance	5
We are One Accord	6
Accord in EMENA	8
Accord in Europe	9
A constantly growing pipeline	10
Product safety	12
Speciality Brands	14
Product added value	16
Digital engagement	17
Manufacturing capabilities	18
Manufacturing & logistics capabilities	20
Manufacturing & packaging capabilities	21
Corporate Responsibility	22
Partner of choice	23



AT A GLANCE



Privately owned
Pharmaceutical company, with rapid decision making



Oncology Leader
c.30% volume share of major chemotherapy molecules*



Biologic Experts
Developing, manufacturing and marketing biologics for over 20 years, one of India's largest r-protein fermentation capacities



Vertical Integration
From development, clinical research, manufacturing, regulatory, commercial and developed back office

REACH



Pharmaceutical Major
\$2.4 Bn USD global sales FY2024



Global Presence
Sales derived from >85 countries, with approx. 50% from EU & US



Accessible Resource
>21,000 Employees including over 7,500 commercial staff globally



Scale and Diversity
14,000 MAs in a myriad of dose forms including, biologics and brands

CAPABILITIES



Strong R&D
Driven by over 560 scientists involved in product development across the globe for small molecules, biologics, cell & gene therapy



Strong Branded Pipeline
Comprising over 15 INNs in portfolio and >30 by FY28/29



Accord Healthcare in the US market
Successfully launched and was recognized for a patient-centric U.S. product with comprehensive patient and HCP support¹



One Stop Shop
Partner of choice for leading developers wanting to access full infrastructure in major markets

INVESTMENT



Animal Health
By adopting NPD[†], In-licensing, JV** and acquisition strategies Accord Animal Health aspires to be a top 20 global manufacturer within the next 10 years



Schimantari site
Our European Hub performing In-House testing, In-house distribution, warehousing and packaging, improving our operations and business performance





Accord Biopharma London
Establishing a Centre of Excellence with state-of-the-art facilities for supporting R&D activities and collaborating with Global R&D in India to accelerate Biosimilars programs



Plasma-Derived Medicinal Products (PDMPs)
Intas/Accord is one of the first and largest plasma fractionators in India and actively exploring expansion opportunities in a global market currently valued at \$35 billion




* European Countries (exc. sales for Lab. Unknown) IQVIA MIDAS MAT May 2024 (KG volume).
NPD[†]: New product development JV** : Joint venture. 1. Product website



GROWING TO BE TOP 10 GENERIC AND BIOSIMILAR PLAYER GLOBALLY

Source: Generics Bulletin Top 50 Ranking for 2024:
The Generics Bulletin Top 50, Part One: Top Ten Ranking
Conceals Changes For Industry Leaders (August 2024)



Part of the Intas Group, Accord is a leading pharmaceutical company in Europe with one of the largest market footprints of any European generic companies, selling medicines in over 85 countries around the world.

Accord continuously strives to 'make it better' by placing the patient at the centre, through its mission to ensure patients gain access to medicines throughout the world.

With one of the most dynamic pipelines in the pharmaceutical industry, Accord has a portfolio of 664 molecules, and an enviable growth strategy, which has seen it continue to grow in terms of both size and scale.



Employing over 2,000 people in EMENA.



Accord is the generic and biosimilar company with **bigger number of CPs*** across Europe.



Pan-European presence in over 45 countries.



One of the most **active launch programmes** in the European generics sector.



14,000 licenses held across Europe, Middle East & North Africa.



Approaching **1,000 new product launches** across EMENA in the last year.



Over **60 oncology and oncology-related treatments** across our portfolio.



A truly integrated pan-regional platform to fulfil our commitment of **improving patient access to high quality vital medicines.**



Business units in **Hospitals, Retail and Speciality Brands.**



DID YOU KNOW?

1 in 3 injectable oncology medicines dispensed in Europe are from Accord.

Source: IQVIA MIDAS MAT
May 2024 (KG volume)

18 oncology molecules
Accord is market leader across Europe.

Source: IQVIA MIDAS MAT
May 2024

* Centralised Procedure

Together as One Accord

Committed to improving patient access to high quality vital medicines.

Accord Healthcare is an award-winning pharmaceutical company dedicated to thinking differently to ensure more patients get the essential medicines they need.

Accord recognises and is passionate about developing the skills and capabilities of its people, which it believes is essential to the continued progress and achievement of its organisational goals.




Together as One Accord

Committed to improving patient access to high quality vital medicines.

Life at Accord is fast-paced and agile. We are driven to achieve results and are committed to delivering with the highest possible standards. All employees are encouraged to challenge themselves to think differently and to deliver more for patients every day.







**EMENA footprint
in over 45 countries:**



**Business
Model:**



*IQVIA MIDAS MAT May 2024 (EUR): Rx bound, Unbranded products, non-biologic molecules, Hospital Sector Exc Belarus, Kazakhstan, Luxemburg, Russia and Turkey. Exc Lab unknown. Exc. ATC A11, A12, A13, K, T




Hospital Sales Ranking

Accord is one of the leading generics companies in Europe, ranking 3rd among the top 10 players (Val.) and leading in Spain

- Top 5
- Top 10
- Top 15
- No data available

*IQVIA MIDAS MAT May 2024 (EUR): Rx bound, Unbranded products, non-biologic molecules, Retail Sector Exc Belarus, Kazakhstan, Luxemburg, Russia and Turkey. Exc Lab unknown. Exc. ATC A11, A12, A13, K, T



Retail Sales Ranking

Accord is ranked within the top 15 generics companies in Europe

- Top 5
- Top 10
- Top 15
- Top 25
- Top 50
- No data available

Accord has one of the most active launch programs in the European generics segment



Exceptional Launch Programme covering 52 Day 1 launches in the last 6 years




Commercialisation of 664 INNs across Europe



Active scanning of launch opportunities for branded, Added Value Products, New Chemical Entities and New Biologic Entities

Others include: Respiratory System, Dermatology, Sensory Organs, Analgesic and Anti-viral
Note: Split on MA counts as of July 2024





Our mission is to enable veterinary professionals and owners to improve the lives of animals through convenient access to affordable and innovative treatments.

accord-animalhealth.com



The current Animal Health vision



Safety Oriented Product Features

Healthcare Professional Safety

Central to our preventative measures is PharmaShield®. A system for our oncology parenteral range consisting of an external shielding and reinforced non-PVC base.

Key benefits of PharmaShield®



The system **reduces risks of potential vial breakage**




Minimises user exposure to external vial contamination



Protects essential **product label information**




Reinforced non-PVC base: provides greater stability when handling with further reduced risk of breakage if the vial is dropped



Unique packaging concept with focus on safety



Our concept consists of **maximising differentiation across our portfolio** by assigning different designs to the strengths within a product range; reducing the likelihood of look-alike sound-alike medication errors



Cross-perforated unit-dose blister

- All relevant information is contained within each perforated blister segment
- No need to reblist tablets or manually cut blisters

Colour differentiated blisters

- Blister's ink colour matches dose colour helping to reduce dispensing errors by clearly differentiating each dose

Barcode included on the blister

- Easy product traceability and dispensation



Speciality Brands aim to deliver enhancements over standard medicines, such as in the way medicines are delivered, to make the experience better for patients and healthcare professionals.

Our portfolio encompasses four essential therapeutic areas:



GCSF:

(Granulocyte Colony Stimulating Factors)



Accord is one of the largest providers of GCSF*

*IQVIA MIDAS MAT May 2024
European Countries (excl. RU, TR), Molecule List: FILGRASTIM, LENOGRASTIM, LIPEGFILGRASTIM, PEGFILGRASTIM



Number of INNs in portfolio.

6

Oncology & Haematology

4

CNS


2

Autoimmune

5


Critical Care

Split of INNs launched since FY 24/25 and planned to launch over the next 5 years



Leader in Oncology

- A leader in global initiatives in formulation work to improve/enhance oncology therapies.
- Strong In House development activities in Speciality Brands area, including NDA (New Drug Application) and value added products, estimated in 63% of total portfolio.
- In Licensing strong scouting activity: in the past 2 years we screened more than 100 opportunities in those Therapeutic Areas and closed many important deals.
- Developing a Unique Lipid-based Patented Platform Technology with the aim to:
 - Improve tolerability gained from surfactant free biphasic formulations
 - Improve safety/efficacy profile
 - Potentially modify PK parameters
 - Enhance Shelf Life
 - US IND Filed; Phase 3 Studies ongoing



Innovative Pipeline:



Over 30 Speciality Brand International Non-proprietary Names (INNs) in the next 5 years.

Patient-centric devices



Intuitive grip

Ergonomically designed to fit the natural contour of a patient's palm, compensating for the loss of grip strength and function caused by rheumatoid arthritis



Easier to plunge

The greater surface area on the handle provides optimum support for the palm, reducing the demand on patient's fingers while making the injection easier to administer



Improved patient safety

Once fully delivered, the device is locked. Passive needle guard activates to withdraw needle point into the device, reducing the risk of needle stick injury



Differentiated Generics

We actively search for innovations to improve our product range and delivery systems to provide HCPs and patients the best value and exceed expectations.

Thanks to this approach we are bringing differentiated generics to better meet HCPs and patients' needs:

New to market dosages where posology may be simplified and adherence improved

New formulations and concentrations that help to optimise and simplify product handling

Higher fill volumes that allow preparing multiple dosages at once thus reducing the number of manipulations required

Extended Stability

In collaboration with renowned university hospitals and experts in this field, we are developing extended stability reports covering our oncology parenteral range and selected general parenteral products with the aim to contribute to improved safety of use, simplified product handling and cost optimisation at the hospital pharmacy.

Unify Help Patient App

For people living with cancer, this app supports patients throughout their journey. It helps locate and speak to community pharmacists, track and monitor symptoms and learn about the condition.




Specialised content from:
The ROYAL MARSDEN
NHS Foundation Trust




Patient App

Designed to support patient adherence with weekly injection reminders. It provides patients how-to-inject animations and digital assets, informing how to safely and effectively perform their self-injections. The app is available for both PFS and SelfDose users.




Injector Support App

The Injector Support App has been designed to improve treatment adherence by reminding patients when to administer the product, providing an easy step-by-step guide to administration and improving a patient's understanding of their condition management.




Digital engagement ecosystem in benefit for HCPs and Patients




Oncodemia Online Training

On cancer care, a specialised toolkit of skills and knowledge on cancer designed specifically for community pharmacy staff.




Product website

Product website providing content for HCPs and patients including support materials such as 'how to use animations' and downloadable patient guides.



Product website

Product website providing content for HCPs and patients including support materials such as 'how to use animations' and downloadable patient guides.



Product website

Product website providing content for HCPs and patients.



Developed with The ROYAL MARSDEN
NHS Foundation Trust

Utilising Accord's manufacturing capabilities and scale to ensure we continue to supply our customers and patients with high-quality and vital medicines.




Significant manufacturing, distribution and testing footprint covering 18 sites – 6 with EU/UK GMP approvals




More than 4,000 manufacturing staff



7 manufacturing, testing and distribution sites in Europe and the UK






Worldwide Presence

-  Effervescents
-  Biological products
-  Solid oral products
-  Injectable products
-  API
-  PLASMA


* Stands for cGMP approved sites
 White boxes denote sites that service Pan-European operations
 Our facilities have undertaken audits and inspections from prominent international regulatory authorities including:
FDA | EMA | MHRA

Vertically integrated with significant EU manufacturing capabilities

7 fully owned sites for manufacturing, distribution and testing in continental Europe.



API | R&D | Clinical | Regulatory | Production Supply
Quality | Sales & Marketing | Pharmacovigilance



SOURCE: Company materials



accord
corporate
responsibility

Our journey to a sustainable future

Accord is fully committed to sustainability and cares about the impact its activities have on the world around us. We believe that we have a purpose and responsibility to make things better for our patients, communities, environment and planet. Accord is on a journey to create a sustainable future and wants to ensure that this journey is transparent, credible, impactful, and measurable.

To achieve this goal, Accord will be expanding its Corporate Responsibility program to include the Environment and Governance.



Environmental:

- Carbon net zero for Scope 1 (direct emissions), Scope 2 (indirect emissions) and Scope 3 - less supply chain by 2045.
- Develop methodology for performing carbon life cycle analysis and complete for top four products, based upon net sales across the Accord network by 2025.
- Zero waste to landfill all UK Operations by 2025.
- Ensure 50% of secondary and tertiary packaging is recyclable, reusable or compostable by end user by 2030 and 100% by 2050.
- Carry out water purity assessment upon our manufacturing sites (Barnstaple and Fawdon) by 2025.
- Encourage the usage of public transport and cycling to work of our staff by 2035.




Social:

- Our early careers initiatives support local school, college and university programs by offering first jobs, graduate and apprenticeship programs. Providing people with the opportunity to learn and grow their careers in STEM (Science, Technology, Engineering and Mathematics) fields.
- Supporting a healthy work environment through men and women's health initiatives.
- Opportunities for careers growth by coaching and mentoring colleagues.



Governance:

- To establish gold standard processes and checks and balances that continue to ensure compliance and transparency for a morally conscious company.



**OUR
ACHIEVEMENTS**

Since our partnership with IHP began in 2013, **Accord Healthcare has donated 2,577,317 units that have supported 3,630,773 patients across 44 countries.**

The 2,577,317 units that have been donated to IHP are **worth the value of approximately £11,304,115.**

Accord products have been included in over 1,407 Essential Health Packs (EHPs) via the IHP. EHPs are pre-packed kits of essential medicines that try and act as a portable pharmacy and are used by IHP as a first line of response when a disaster strikes, enabling communities in hard-to-reach places to access the medicines they need. **Between 2016 and 2023, Accord have supported IHP's disaster response and health programmes with £117,000 in funding.**



Partner of choice for generics, biosimilars and novel therapeutics



Vertical Integration

- Resilient supply chain with local packing
- Clinical competence



Commercial Strength

- Global reach
- Omnichannel and digital marketing



Regulatory Expertise

- Access to 35+ European markets
- Expertise with competent authorities



In-licensing and M&A Track Record

- Complex carve-out experience
- Due diligence and technology transfer
- First NCE launched in 2022, only three months after signing the deal.



Manufacturing Capabilities

- Scale
- Complexity
- UK and India sites

